Prediction of Hyperkalemia in Dialysis Patients Through Waveform Analysis Using Wearable ECG

Launched by KYUNGHO PARK · Jun 27, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a wearable heart monitor can help detect high potassium levels (called hyperkalemia) early in patients who are on dialysis because of chronic kidney disease. High potassium can be dangerous, so finding it quickly is important. The study will have patients wear a small, chest-attached device that records their heart’s electrical activity during dialysis sessions. Researchers will look at the heart’s signals, especially parts called T waves, to see if changes match up with blood potassium levels measured during regular blood tests. This non-invasive, real-time monitoring could help doctors spot problems sooner without needing extra blood draws.

Adults aged 19 and older who have chronic kidney disease and are receiving hemodialysis three times a week may be eligible for this study, as long as they are in stable condition and can wear the ECG device without trouble. Participants will wear the device during four dialysis sessions over six weeks, while their potassium levels are checked through routine blood tests. The study does not involve any treatment changes and focuses on observing how well the device works for monitoring potassium levels safely and comfortably.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged 19 years or older
• • Diagnosed with chronic kidney disease (CKD) and receiving maintenance hemodialysis three times per week
• • Stable clinical condition without acute complications in the past 3 months
• • Ability to understand and sign informed consent
• • No physical or physiological barrier to wearing an ECG device
• Exclusion Criteria:
• • Significant skin conditions (e.g., severe dermatitis, burns) that prevent ECG device attachment
• • Refusal or inability to comply with study procedures